CYP2C19 pharmacogenetics in the clinical use of proton‐pump inhibitors for gastro‐oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms
Open Access
- 20 June 2003
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (12) , 1521-1528
Abstract
Summary: Background: The rate of metabolic inactivation of proton‐pump inhibitors is determined by polymorphisms of CYP2C19. It is not known if CYP2C19 variant alleles affect responses to proton‐pump inhibitor therapy in gastro‐oesophageal reflux disease (GERD).Aim: To determine if the CYP2C19 genotype is associated with clinical effectiveness of proton‐pump inhibitors during GERD therapy.Methods: GERD patients undergoing ambulatory gastric and oesophageal pH monitoring were genotyped for CYP2C19 polymorphisms.Results: Sixty subjects were enrolled. Forty‐four subjects had two wild‐type alleles, 15 had one variant, and one had two variant CYP2C19 alleles. The presence of a variant allele was significantly associated with a lower odds of gastric acid breakthrough during proton‐pump inhibitor therapy [odds ratio 5.14, 95% confidence interval (CI) 1.17–22.61]. The presence of a variant allele was not associated with a lower odds of significant oesophageal acid exposure (odds ratio 2.50, 95% CI 0.60–10.52), or the occurrence of symptoms (incidence rate ratio 1.06, 95% CI 0.54–2.06).Conclusions: These results indicate that factors other than gastric acid secretion are important determinants of reflux in GERD patients. This suggests that CYP2C19 genotype testing will not be useful in proton‐pump inhibitor therapy of GERD, except perhaps in identifying patients at risk for hypochlorhydria and consequent hypergastrinemia.Keywords
This publication has 30 references indexed in Scilit:
- Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disordersAlimentary Pharmacology & Therapeutics, 2000
- genotype status and effect of omeprazole on intragastric pH in humansClinical Pharmacology & Therapeutics, 1999
- Treatment of Helicobacter pylori InfectionArchives of internal medicine (1960), 1998
- An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in CaucasiansPharmacogenetics, 1998
- Nonprescription H2-Receptor AntagonistsJournal of the American Pharmaceutical Association, 1997
- Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects*Clinical Pharmacology & Therapeutics, 1996
- A Comparison of Five Maintenance Therapies for Reflux EsophagitisNew England Journal of Medicine, 1995
- Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and SafetyAnnals of Internal Medicine, 1994
- Rolling review: gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1993
- Barrett's esophagus: Age, prevalence, and extent of columnar epitheliumGastroenterology, 1992